Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
migraine
4
×
national blog main
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
national
national top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bausch health
cancer
cancer immunotherapy
dihydroergotamine
fda
fremanezumab
galcanezumab
gene therapy
glaxosmithkline
impel neuropharma
What
companies
4
×
drug
approval
bio
ipo
migraine
new
roundup
activity
arena’s
arguments
big
biogen’s
biopharmaceutical
biotech
bounty
cig
class
comeback
commercialized
competitors
convo
corner
days
deals
decades
delivered
dog
drugs
earlier
expressing
failures
fda
firm
hasn’t
ipos
leading
life
line
littered
Language
unset
Current search:
migraine
×
companies
×
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More